ImpediMed

ImpediMed OCF Margin

The Operating Cash Flow Margin of ImpediMed (IPD.AX) as of Sep 27, 2026 is -137.08 %. In the previous year, Operating Cash Flow Margin was -115.10 % — a change of 19.10% (lower).

OCF Margin

-137.08 %

YoY

19.10%

Last updated:

Operating Cash Flow Margin of ImpediMed is 2026 -137.08 % . Operating Cash Flow Margin of ImpediMed was 2025 -115.10 % . It decreases by 19.10% lower compared to the previous year.

The ImpediMed OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2019
-471.32 AUD
Jan 1, 2020
-334.75 AUD
Jan 1, 2021
-157.66 AUD
Jan 1, 2022
-148.25 AUD
Jan 1, 2023
-159.11 AUD
Jan 1, 2024
-172.39 AUD
Jan 1, 2025
-115.10 AUD
Jan 1, 2026
-137.08 AUD
The ImpediMed OCF Margin history
YEAROCF MarginYoY
-137.08 %+19.10%
-115.10 %-33.23%
-172.39 %+8.35%
-159.11 %+7.32%
-148.25 %-5.97%
-157.66 %-52.90%
-334.75 %-28.98%
-471.32 %-33.33%
-706.99 %+59.45%
-443.39 %+14.52%
-387.19 %+74.35%
-222.07 %+14.95%
-193.18 %—
Access this data via the Eulerpool API

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Operating Cash Flow Margin of ImpediMed is -137.08 % in 2026.

Operating Cash Flow Margin of ImpediMed changed from -115.10 % to -137.08 %, representing a 19.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin ImpediMed since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's ImpediMed with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — ImpediMed

All Key Metrics — ImpediMed